Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.71B
Close$
$-24.68
190.2% downside
Current Fair Value
190.2% downsideOvervalued by 190.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.71 Billion |
|---|---|
| Enterprise Value | $5.00 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.1 |
| Outstanding Shares | 157,700,126 |
Return
| Return on Equity | -44.68% |
|---|---|
| Return on Assets | -9.97% |
| Return on Invested Capital | -6.60% |
Valuation & Multiples
| P/E Ratio | -72.24 |
|---|---|
| PEG | -130.54 |
| Price to Sales | 27.37 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 16.24 |
| Enterprise Value to EBIT | -137.21 |
| Enterprise Value to Net Income | -79 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 3.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$71.64 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0046▼ 14.65% |
|---|---|
| Total Calls | 6,764,620▲ 8789.12% |
| Total Puts | 31,200▲ 171.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 398.23%▲ 7.45% |
|---|---|
| Total Invested | $3.37B▲ 59.62% |
| Investors Holding | 309▲ 7.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...